¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"gradient echo imaging"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • fast spin echo
    °í¼Ó½ºÇÉ¿¡ÄÚ
  • hepatorenal echo contrast
    °£ÄáÆÏ¸Þ¾Æ¸®´ëÁ¶, °£½ÅÀå¿¡ÄÚ´ëÁ¶
  • homogeneous echo pattern
    ±ÕÁú¸Þ¾Æ¸®¾ç»ó
  • low echo area
    ³·Àº¸Þ¾Æ¸®¿µ¿ª, Àú¿¡ÄÚ¿µ¿ª
  • navigator echo technique
    Ç×ÇØ¿¡ÄÚ±â¹ý
  • odd echo dephasing
    Ȧ¼ö¿¡ÄÚÅ»À§»ó
  • pulse echo principle
    ÆÞ½º¿¡ÄÚ¿ø¸®
  • pulse-echo technique
    ÆÞ½º¿¡ÄÚ±â¹ý
  • reverberation echo
    ¹ÝÇâ¸Þ¾Æ¸®, ¹ÝÇâ¿¡ÄÚ
  • spin echo
    ½ºÇÉ¿¡ÄÚ
  • spin echo pulse sequence
    ½ºÇÉ¿¡ÄÚÆÞ½º¿¬¼â
  • spin echo technique
    ½ºÇÉ¿¡ÄÚ±â¹ý
  • stimulated echo acquisition mode
    Àڱظ޾Ƹ®È¹µæ¹æ½Ä, Àڱؿ¡ÄÚȹµæ¸ðµå
  • semiliquid echo pattern
    ¹Ý¾×ü¿¡ÄÚ¾ç»ó
  • simulated echo technique
    ¸ðÀÇ¿¡ÄÚ±â¹ý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • echo
    ¸Þ¾Æ¸®, ¹ÝÇâ, ¿¡ÄÚ, ÃÊÀ½ÆÄ-
  • echo-pulse
    ¸Þ¾Æ¸®¸Æ
  • echo intensity
    ¸Þ¾Æ¸®°­µµ
  • echo pulse
    ÃÊÀ½ÆÄ, ¸Þ¾Æ¸®ÆÄ
  • echo sign
    ¸Þ¾Æ¸®Â¡ÈÄ
  • echo train sequence
    ¿¡ÄÚ¿­¿¬¼â
  • even echo rephasing
    ¦¼ö¿¡ÄÚÀçÀ§»ó
  • fast spin echo
    °í¼Ó½ºÇÉ¿¡ÄÚ
  • reverberation echo
    ¹ÝÇâ¸Þ¾Æ¸®
  • spin echo
    ½ºÇɸ޾Ƹ®, ½ºÇÉ¿¡ÄÚ
  • spin echo examination
    ½ºÇÉ¿¡ÄÚ°Ë»ç
  • stimulated echo
    Àڱظ޾Ƹ®
  • homogeneous echo pattern
    ±ÕÁú¸Þ¾Æ¸®¾ç»ó
  • midline echo shift
    Á¤Áß¼±¸Þ¾Æ¸®º¯À§
  • stimulated echo acquisition mode
    Àڱظ޾Ƹ®È¹µæ¹æ½Ä
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • imaging modality
    ¿µ»ó±â¹ý
  • imaging of STIR sequence
    STIR ¿¬¼â ¿µ»ó
  • imaging parameter
    ¿µ»ó ÁöÇ¥, ¿µ»ó º¯¼ö
  • imaging procedure
    ¿µ»ó ÀýÂ÷
  • imaging sequence
    ¿µ»ó ¿¬¼â
  • phase offset multiplannar (POMP) imaging
    À§»ó ¿ÀÇÁ¼Â ´Ù¸é ¿µ»ó
  • radionuclide imaging
    ¹æ»ç¼º ÇÙÁ¾À̸ÞÀÌ¡.
  • real time imaging
    ½Ç½Ã°£ ¿µ»ó ±â¹ý
  • receptor imaging
    ¼ö¿ëü¿µ»ó(È­)
  • B1 field gradient
    ȸÀü ÀÚÀå Àڱ⠰æ»ç
  • Ficoll-Hypaque gradient centrifugation
    ÇÇÄÝ-ÇÏÀÌÆÑ ¹Ðµµ±¸¹è ¿ø½ÉºÐ¸®
  • Ion gradient
    À̿°æ»ç(ÌËÞØ)
  • X gradient
    XÃà °æ»ç
  • Y gradient
    YÃà °æ»ç
  • Z gradient
    ZÃà °æ»ç
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • first-pass MR imaging
    ÀÏÂ÷ Åë°ú ÀÚ±â°ø¸í¿µ»ó
  • frequency modulation imaging
    Á֯ļö º¯Á¶ ¿µ»ó
  • frequency-modulation imaging
    Á¶ÆÄ¼ö Á¶Á¤ ¿µ»ó (ñ²÷î⦠ðàïÚ ç±ßÀ)
  • functional brain imaging
    ±â´ÉÀû ³ú¿µ»ó
  • functional magnetic resonance imaging (fMRI)
    ±â´ÉÀû ÀÚ±â°ø¸í¿µ»ó
  • half Fourier imaging
    ¹Ý Fourier ¿µ»ó
  • hybrid imaging
    È¥¼º ¿µ»ó
  • imaging
    ¿µ»ó
  • imaging
    »ó»ó,¿µ»ó
  • imaging modality
    ¿µ»ó±â¹ý
  • imaging of STIR sequence
    STIR ¿¬¼â ¿µ»ó
  • imaging parameter
    ¿µ»ó ÁöÇ¥, ¿µ»ó º¯¼ö
  • imaging procedure
    ¿µ»ó ÀýÂ÷
  • imaging sequence
    ¿µ»ó ¿¬¼â
  • intravoxel coherent motion (IVCM) imaging
    º¹¼¿³» °áÁý ¿îµ¿ ¿µ»ó
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • frequency modulation imaging
    Á֯ļöº¯Á¶¿µ»ó
  • functional brain imaging
    ±â´ÉÀû³ú¿µ»ó
  • functional magnetic resonance imaging [=fMRI]
    ±â´ÉÀûÀÚ±â°ø¸í¿µ»ó
  • half Fourier imaging
    ¹ÝFourier¿µ»ó
  • hybrid imaging
    È¥¼º¿µ»ó
  • imaging
    ¿µ»ó
  • imaging modality
    ¿µ»ó±â¹ý
  • imaging of STIR sequence
    STIR¿¬¼â¿µ»ó
  • imaging parameter
    ¿µ»óÁöÇ¥, ¿µ»óº¯¼ö
  • imaging procedure
    ¿µ»óÀýÂ÷
  • imaging procedure
    ¿µ»óÁø´Ü¹ý
  • imaging sequence
    ¿µ»ó¿¬¼â
  • intravoxel coherent motion [=IVCM] imaging
    º¹¼¿³»°áÁý¿îµ¿¿µ»ó
  • intravoxel incoherent motion [=IVIM] imaging
    º¹¼¿³»ºñ°áÁý¿îµ¿¿µ»ó
  • magnetic resonance imaging [=MRI]
    ÀÚ±â°ø¸í¿µ»ó
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
AAG 3-alkaladenine deoxyribonucleic acid glycosylase; allergic angiitis and granulomatosis; alpha-1-acid...
CGGE constant gradient gel electrophoresis
DGGE denaturating gradient gel electrophoresis
ECPOG electrochemical potential gradient
GEPG gastroesophageal pressure gradient
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
NEPHGE Nonequilibrium pH gradient electrophoresis
PCR-DGGE Polymerase chain reaction-denaturing gradient gel electrophoresis
PFG Pulse field gradient
SAAG Serum-Ascites Albumin Gradient
SDG Sucrose density gradient
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • partial volume imaging
    ºÎºÐ ¿ëÀû ¿µ»ó
  • perfusion and diffusion imaging
    °ü·ù È®»ê ¿µ»ó
  • radionuclide imaging
    ¹æ»ç¼º ÇÙÁ¾ »ó
  • shock wave imaging
    Ãæ°ÝÆÄ »ó
  • stop action imaging
    Á¤Áö »óÅ ¿µ»ó
  • T1 weighted FLASH imaging
    T1 °­Á¶ FLASH ¿µ»ó
  • ultrasonic imaging
    ÃÊÀ½ÆÄ ¿µ»ó
  • Zebra-stripe imaging method
    ¾ó·è¸» ¹«´Ì ¿µ»ó ¹æ¹ý
  • backscatter echo
    ÈÄ¹æ »ê¶õ ¿¡ÄÚ
  • bottom echo
    ¹Ù´Ú ¿¡ÄÚ
  • capsular echo
    ÇǸ· ¿¡ÄÚ
  • central renal echo complex
    ½Å Á᫐ ¿¡ÄÚ º¹ÇÕü
  • echo amplitude
    ¿¡ÄÚ Å©±â
  • echo free
    ¿¡ÄÚ°¡ ¾ø´Â, ¹«¿¡ÄÚÀÇ
  • echo pattern
    ¿¡ÄÚ ¾ç»ó
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
myocardial infarct imaging <radiology> Tc-99m pyrophosphate (PYP) 20 mCi, peak abnormality 2-3 days, often falsely negative before 2 days, abnormal for 7-10 days, mechanism: calcium influx into ischemic cells, PYP incorporated into crystalline structure, analogous to hydroxyapatite see: nuclear cardiology
(12 Dec 1998)
myocardial perfusion imaging <radiology> (thallium scanning) thallium (Tl) 201, acts as potassium analog, dose 2.0 - 3.0 mCi at peak exercise, 4% of injected dose reaches myocardium, imaging: exercise (1-5 min), redistribution (3-4 hrs), views: anterior, LAO 45', left lateral, interpretation: normal, reversible abnormalitymost likely to be exercise-induced ischemia, nonreversible abnormalitymost likely to be prior myocardial infarction, reverse redistribution most likely to be normal areas wash out faster, lung activity most likely to be LV failure during exercise see also: dipyridamole test, nuclear cardiology
(12 Dec 1998)
hepatobiliary imaging <radiology> The hepatobiliary scan (Tc-99m DISIDA or MBF) is the initial procedure of choice to diagnose acute cholecystitis., Sensitivity 95% False negatives: acalculous cholecystitis, Specificity 95% False positives: non-fasting state, alcoholism, parenteral nutrition (TPN), acute pancreatitis, recent narcotic use, hepatocellular disease
(12 Dec 1998)
high-resolution imaging <technique> High Resolution Electron Microscopy is phase contrast microscopy of the atomic structure of materials. In most crystalline inorganic materials and a number of polymeric materials HREM allows the imaging of individual atomic columns. The images can frequently be interpreted in terms of the projected crystal potential, although it is often necessary to match the experimental images with those calculated from multislice algorithms. Allows direct measurement of lattice parameters, inspection of individual defects and grain orientation.
(05 Aug 1998)
secondary electron imaging <microscopy> Production of secondary electrons is very topography related. Due to their low energy, 5eV, only secondaries that are very near the surface (less than 10nm) can exit the sample and be examined. Any changes in topography in the sample that are larger than this sampling depth will change the yield of secondaries due to collection efficiencies. Collection of these electrons is aided by using a collector in conjunction with the secondary electron detector. The collector is a grid or mesh with a +100V potential applied to it which is placed in front of the detector, attracting the negatively charged secondary electrons to it which then pass through the grid-holes and into the detector to be counted. When a Secondary Electrons collide with the solid-state saemiconductor detector an electron-hole pairs are created which are then counted. This quantity is translated into a pixel intensity and displayed on the CRT, forming the image.
(05 Aug 1998)
neoplasm: gallium imaging <radiology> Useful: Hodgkin disease and histiocytic form of NHL poor sensitivity below the diaphragm, Burkitt lymphoma: almost 100% sensitivity, hepatoma: 90% sensitivity, melanoma: 90% sensitivity, leukaemia possibly useful: NHL: good for large and mediastinal lesions, nodal metastases from seminoma and embryonal cell carcinoma: 87% sensitivity, non-small cell lung CA: 85% sensitive not useful: head and neck, GI (especially adenocarcinoma), breast, gynaecological, kiddie tumours see: gallium: indications
(12 Dec 1998)
nuclear magnetic resonance imaging A special imaging technique used to image internal stuctures of the body, particularly the soft tissues. An MRI image is often superior to a normal X-ray image.
It uses the influence of a large magnet to polarize hydrogen atoms in the tissues and then monitors the summation of the spinning energies within living cells.
Images are very clear and are particularly good for soft tissue, brain and spinal cord, joints and abdomen. These scans may be used for detecting some cancers or for following their progress.
Acronym: MRI
(11 Nov 1997)
dark field imaging <microscopy> Using a single diffracted beam to form the image in a transmission electron microscope. This causes all regions of the specimen not of the same crystal structure and orientation as the region which produced the diffracted beam to be represented as very dark in the final image, allowing phase differentiation visually in the transmission electron microscope.
(05 Aug 1998)
diagnostic imaging Any visual display of structural or functional patterns of organs or tissues for diagnostic evaluation. It includes measuring physiologic and metabolic responses to physical and chemical stimuli, as well as ultramicroscopy.
(12 Dec 1998)
dipyridamole-thallium imaging <radiology> Myocardial perfusion imaging for patients who cannot exercise, dipyridamole, potent coronary vasodilator, dose: 300 mg IV, side effects relieved by aminophyllin, thallium given when: symptomatic, HR increased 10 bpm, diastolic BP decreased 10 mm Hg, 45 min after PO dose
(12 Dec 1998)
imaging Radiological production of a clinical image using X-rays, ultrasound, computed tomography, magnetic resonance, radionuclide scanning, thermography, etc.; especially, cross-sectional imaging, such as ultrasonography, CT, or MRI.
Origin: see image
(05 Mar 2000)
imaging agents Proteins developed to act as imaging or contrast agents for use with various types of bodyscanners. The proteins, usually antibodies, bind to specific tissue types, usually tumours, and allow the scanner to distinguish those tissues from the surrounding tissue very easily.
(14 Nov 1997)
imaging department The diagnostic radiology department.
See: imaging, radiology.
(05 Mar 2000)
inflammation: gallium imaging <radiology> Pathophysiology: leakage of protein-bound Ga-67 into extracellular space secondary to increased capillary permeability, Ga-67 is preferentially bound to nonviable PMNs and macrophages, leukocyte incorporation (rich in lactoferrin), bacterial uptake (siderophores), inflammtory tissue stimulates lactoferrin production for chronic abdominal inflammation: 67% sensitivity; 64% specificity; 13% false negatives; 5% false positive, dose: 5 mCi; imaging: 24, 48, 72 hours, diffuse uptake in peritonitis, localised uptake in acute pyogenic abscess, phlegmon, acute cholecystitis, acute pancreatitis, acute gastritis, diverticulitis, inflammatory bowel disease, surgical wound, pyelonephritis, perinephric abscess see: gallium indications, gallium vs. Indium
(12 Dec 1998)
through transfer imaging The production of an ultrasound image by detection and analysis of sound on the opposite side of the body from the emitting transducer.
Synonym: through transfer imaging.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á